체외진단(IVD) 시장 : 규모, 점유율 및 동향 분석 보고서 - 제품별, 검사 장소별, 최종 용도별, 용도별, 기술별, 지역별, 부문 예측(2025-2030년)

In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test Location, By End Use, By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,356,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,760,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,569,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

체외진단(IVD) 시장 성장과 동향 :

세계의 체외진단(IVD) 시장 규모는 2030년에는 1,501억 3,000만 달러에 달할 것으로 예측되고, 2025년부터 2030년에 걸쳐 CAGR 5.62%를 나타낼 것으로 전망됩니다.

노인 인구 증가, COVID-19의 유행, 진단의 기술 진보가 보급을 뒷받침하고 있습니다. 휴대성, 정확성, 비용 효율성 측면에서 기술 진보는 영향력이 큰 렌더링 촉진 요소 중 하나로 예측됩니다. 기술의 진보는 COVID-19의 체외진단제의 발매에 의해 더욱 가속되어 PCR과 같은 기술을 위한 장치나 소모품의 채용을 강화했습니다. 이 시장의 경쟁사들은 제조업체와 사용자의 비즈니스 흐름을 일정하게 유지하기 위해 계약 및 파트너십 전략을 채택하고 있습니다.

이러한 계약은 또한 정부의 실험실에 대한 엄격한 가격 억제 전략의 결과이며, 정부 설정의 가격을 낮추고 있습니다. 예를 들어, 2021년 4월, Seegene, Inc.의 이탈리아 자회사는 715만 건의 SARS-CoV-2 진단 테스트뿐만 아니라 추출 시약 공급을 위한 공공 조달을 위해 1억 825만 달러의 입찰을 받았습니다. SARS-CoV-2 진단 검사는 SARS-CoV-2 진단 검사와 SARS-CoV-2 추출 시약을 공급하는 것이 주요 목적이지만 공급망의 다자간 거래와 복잡성이 증가합니다. 암과 심혈관질환(CVDs)의 세계 유병률이 높아짐에 따라 조기진단을 촉진하고 소비자의 끊임없이 진화하는 요구에 부응하기 위한 진단기술 혁신을 촉진할 것으로 예상됩니다. Plasmonic PCR과 같은 새로운 기술은 예측 기간 동안 상업적으로 시장에 진입하고 기존 제품의 비즈니스에 부정적인 영향을 미칠 것으로 예상됩니다.

체외진단(IVD) 시장 : 분석 개요

• 체외진단(IVD) 시장은 분자진단, 차세대 시퀀싱(NGS), PoC 검사의 진보에 견인되어 첨단 기술 혁신을 보여줍니다.
• 체외진단(IVD) 시장의 유통 채널은 제품이 의료 시설, 실험실 및 최종 사용자에게 어떻게 도달하는지에 중요한 역할을 하며 시장에 도달하고 업무 효율성에 영향을 미칩니다.
• 체외진단(IVD) 제품 가격은 제품 유형, 복잡성 및 용도에 따라 크게 다릅니다.
• 시약은 2024년 체외진단(IVD) 시장에서 65.54%의 최대 점유율을 차지해 혁신적인 바이오마커 키트의 개발을 목표로 하는 대기업 시장 기업의 연구개발 노력이 큰 원동력이 되었습니다.
• 북미가 체외진단 업계를 지배했으며 2024년에는 47.43%의 점유율을 차지했습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 체외진단(IVD) 시장 : 변동 요인·동향·범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회의 분석
  • 공급망 분석
  • 유통 채널
• 체외진단(IVD) 시장 : 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
• IVD 및 LDT의 환급 개요
• 가격 분석

제4장 체외진단(IVD) 시장 : 제품별 추정·동향 분석

• 부문 대시보드
• 체외진단(IVD) 시장 : 변동 분석, 제품별(2024년, 2030년)
• 장치
• 장치 : 시장 수익 추계·예측(금액(10억 달러), 수량(1,000대), 2018-2030년)
• 시약
• 서비스

제5장 체외진단(IVD) 시장 : 기술별 추정·동향 분석

• 부문 대시보드
• 체외진단(IVD) 시장 : 변동 분석, 기술별(2024년, 2030년)
• 면역 분석
  • 장치
  • 시약
  • 서비스
• 혈액학
  • 장치
  • 시약
  • 서비스
• 임상 화학
  • 장치
  • 시약
  • 서비스
• 분자진단
  • 장치
  • 시약
  • 서비스
• 응고
  • 장치
  • 시약
  • 서비스
• 미생물학
  • 장치
  • 시약
  • 서비스
• 기타
  • 장치
  • 시약
  • 서비스

제6장 체외진단(IVD) 시장 : 용도별 추정·동향 분석

• 부문 대시보드
• 체외진단(IVD) 시장 : 변동 분석, 용도별(2024년, 2030년)
• 감염병
• 당뇨병
• 종양학/암
• 심장학
• 신장학
• 자가면역질환
• 약물 검사
• 기타

제7장 체외진단(IVD) 시장 : 검사 장소별 추정·동향 분석

• 부문 대시보드
• 체외진단(IVD) 시장 : 변동 분석, 검사 장소별(2024년, 2030년)
• PoC
• 재택치료
• 기타

제8장 체외진단(IVD) 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 체외진단(IVD) 시장 : 변동 분석, 최종 용도별(2024년, 2030년)
• 병원
• 연구실
• 재택치료
• 기타

제9장 체외진단(IVD) 시장 : 지역별 추정·동향 분석

• 체외진단(IVD) 시장 점유율 : 지역별(10억 달러, 2024년, 2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 덴마크
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 남아프리카
  • 쿠웨이트

제10장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업 분류
• 세계 기업의 시장 점유율 분석 보고서(2024년)
• 기업 히트맵 분석
• 전략 매핑
  • 확대
  • 기업 합병·인수(M&A)
  • 파트너십 및 협업
  • 신제품 발매
  • 연구개발
• 기업 프로파일
  • Abbott
  • Bio-Rad Laboratories, Inc
  • Siemens Healthineers AG
  • BIOMERIEUX
  • BD
  • QIAGEN
  • Quidel Corporation
  • F. Hoffmann-La Roche Ltd.
  • Danaher
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc.

KTH

영문 목차

영문목차

In Vitro Diagnostic Market Growth & Trends:

The global in vitro diagnostics market size is expected to reach USD 150.13 billion in 2030 and is projected to grow at a CAGR of 5.62% from 2025 to 2030. driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

In Vitro Diagnostics Market Report Highlights:

• The IVD market demonstrates a high degree of innovation, driven by advancements in molecular diagnostics, next-generation sequencing (NGS), and point-of-care testing.
• The distribution channels for in vitro diagnostics (IVD) market play a critical role in how products reach healthcare facilities, laboratories, and End Users, impacting market reach and operational efficiency
• The pricing of In vitro diagnostics (IVD) products varies significantly based on product type, complexity, and application.
• Reagents held the largest share of 65.54% of the in vitro diagnostics market in 2024, driven by significant R&D efforts from leading market players aiming to develop innovative biomarker kits
• North America dominated the in vitro diagnostics industry and accounted for a 47.43% share in 2024

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. Test Location
  • 1.2.5. End Use
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
• 1.7. Details of primary research
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.1.1. Approach 1: Commodity flow approach
  • 1.9.2. Volume price analysis (Model 2)
    • 1.9.2.1. Approach 2: Volume price analysis
• 1.10. Research Scope and Assumptions
  • 1.10.1. List of Secondary Sources
  • 1.10.2. List of Primary Sources
  • 1.10.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. In Vitro Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Introduction of Technologically Advanced Products
    • 3.2.1.2. Increasing Demand for PoC Testing
    • 3.2.1.3. Growing Prevalence of Target Diseases
    • 3.2.1.4. Increasing External Funding for R&D
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Presence of Ambiguous Regulatory Framework
    • 3.2.2.2. High Capital Investment
    • 3.2.2.3. High Prices of Molecular Diagnostic Tests
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Supply Chain Analysis
  • 3.2.5. Distribution Channel
    • 3.2.5.1. Direct Sales
    • 3.2.5.2. Distributors Network
    • 3.2.5.3. E-commerce and Online Platforms
    • 3.2.5.4. Major Distributors
• 3.3. In Vitro Diagnostics Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Legal landscape
• 3.4. Reimbursement Overview of IVDs and LDTs
• 3.5. Pricing Analysis

Chapter 4. In Vitro Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. In Vitro Diagnostics Market: Product Movement Analysis, 2024 & 2030 (USD Billion)
• 4.3. Instruments
• 4.4. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)Reagents
  • 4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
• 4.5. Services
  • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. In Vitro Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. In Vitro Diagnostics Market: Technology Movement Analysis, 2024 & 2030 (USD Billion)
• 5.3. Immunoassay
  • 5.3.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.3.2. Instruments
    • 5.3.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Units)
  • 5.3.3. Reagents
    • 5.3.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.3.4. Services
    • 5.3.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Hematology
  • 5.4.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.4.2. Instruments
    • 5.4.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)
  • 5.4.3. Reagents
    • 5.4.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.4.4. Services
    • 5.4.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Clinical Chemistry
  • 5.5.1. Clinical Chemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.5.2. Instruments
    • 5.5.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)
  • 5.5.3. Reagents
    • 5.5.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.5.4. Services
    • 5.5.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Molecular Diagnostics
  • 5.6.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.6.2. Instruments
    • 5.6.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)
  • 5.6.3. Reagents
    • 5.6.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.6.4. Services
    • 5.6.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Coagulation
  • 5.7.1. Coagulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.7.2. Instruments
    • 5.7.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)
  • 5.7.3. Reagents
    • 5.7.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.7.4. Services
    • 5.7.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. Microbiology
  • 5.8.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.8.2. Instruments
    • 5.8.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)
  • 5.8.3. Reagents
    • 5.8.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.8.4. Services
    • 5.8.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 5.9.2. Instruments
    • 5.9.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands)
  • 5.9.3. Reagents
    • 5.9.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Reagents, Number of Tests in Million)
  • 5.9.4. Services
    • 5.9.4.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. In Vitro Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. In Vitro Diagnostics Market: Application Movement Analysis, 2024 & 2030 (USD Billion)
• 6.3. Infectious Disease
  • 6.3.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Diabetes
  • 6.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Oncology/Cancer
  • 6.5.1. Oncology/Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Cardiology
  • 6.6.1. Cardiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.7. Nephrology
  • 6.7.1. Nephrology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.8. Autoimmune Diseases
  • 6.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.9. Drug Testing
  • 6.9.1. Drug Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.10. Others
  • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. In Vitro Diagnostics Market: Test Location Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. In Vitro Diagnostics Market: Test Location Movement Analysis, 2024 & 2030 (USD Billion)
• 7.3. Point of Care
  • 7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Home-care
  • 7.4.1. Home-care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Others
  • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. In Vitro Diagnostics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. In Vitro Diagnostics Market: End Use Movement Analysis, 2024 & 2030 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 8.4. Laboratory
  • 8.4.1. Laboratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 8.5. Home Care
  • 8.5.1. Home Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 8.6. Others
  • 8.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)

Chapter 9. In Vitro Diagnostics Market: Regional Estimates & Trend Analysis

• 9.1. In Vitro Diagnostics Market Share, By Region, 2024 & 2030, USD Billion
• 9.2. North America
  • 9.2.1. North America In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Regulatory Landscape/Reimbursement Scenario
    • 9.2.2.3. Competitive Insights
    • 9.2.2.4. U.S. In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Regulatory Landscape/Reimbursement Scenario
    • 9.2.3.3. Competitive Insights
    • 9.2.3.4. Canada In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Regulatory Landscape/Reimbursement Scenario
    • 9.2.4.3. Competitive Insights
    • 9.2.4.4. Mexico In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 9.3. Europe
  • 9.3.1. Europe In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.2. U.K.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.2.3. Competitive Insights
    • 9.3.2.4. U.K. In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.3.3. Competitive Insights
    • 9.3.3.4. Germany In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.4.3. Competitive Insights
    • 9.3.4.4. France In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.5.3. Competitive Insights
    • 9.3.5.4. Italy In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.6.3. Competitive Insights
    • 9.3.6.4. Spain In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.7. Sweden
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.7.3. Competitive Insights
    • 9.3.7.4. Sweden In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.8. Denmark
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.8.3. Competitive Insights
    • 9.3.8.4. Denmark In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Regulatory Landscape/Reimbursement Scenario
    • 9.3.9.3. Competitive Insights
    • 9.3.9.4. Norway In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4.2. China
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 9.4.2.3. Competitive Insights
    • 9.4.2.4. China In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.4.3. Japan
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 9.4.3.3. Competitive Insights
    • 9.4.3.4. Japan In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 9.4.4.3. Competitive Insights
    • 9.4.4.4. India In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.4.5. South Korea
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Regulatory Landscape/Reimbursement Scenario
    • 9.4.5.3. Competitive Insights
    • 9.4.5.4. South Korea In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.4.6. Australia
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Regulatory Landscape/Reimbursement Scenario
    • 9.4.6.3. Competitive Insights
    • 9.4.6.4. Australia In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Regulatory Landscape/Reimbursement Scenario
    • 9.4.7.3. Competitive Insights
    • 9.4.7.4. Thailand In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 9.5. Latin America
  • 9.5.1. Latin America In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 9.5.2.3. Competitive Insights
    • 9.5.2.4. Brazil In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 9.5.3.3. Competitive Insights
    • 9.5.3.4. Argentina In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
• 9.6. Middle East and Africa
  • 9.6.1. Middle East and Africa In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.6.2. Saudi Arabia
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 9.6.2.3. Competitive Insights
    • 9.6.2.4. Saudi Arabia In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.6.3. UAE
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 9.6.3.3. Competitive Insights
    • 9.6.3.4. UAE In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.6.4. South Africa
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 9.6.4.3. Competitive Insights
    • 9.6.4.4. South Africa In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 9.6.5.3. Competitive Insights
    • 9.6.5.4. Kuwait In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion) (Volume, Number of Instruments, in Thousands) (Volume, Reagents, Number of Tests in Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Global Company Market Share Analysis, 2024
• 10.4. Company Heat Map Analysis
• 10.5. Strategy Mapping
  • 10.5.1. Expansion
  • 10.5.2. Mergers & Acquisition
  • 10.5.3. Partnerships & Collaborations
  • 10.5.4. New Product Launches
  • 10.5.5. Research And Development
• 10.6. Company Profiles
  • 10.6.1. Abbott
    • 10.6.1.1. Participant's Overview
    • 10.6.1.2. Financial Performance
    • 10.6.1.3. Product Benchmarking
    • 10.6.1.4. Recent Developments
  • 10.6.2. Bio-Rad Laboratories, Inc
    • 10.6.2.1. Participant's Overview
    • 10.6.2.2. Financial Performance
    • 10.6.2.3. Product Benchmarking
    • 10.6.2.4. Recent Developments
  • 10.6.3. Siemens Healthineers AG
    • 10.6.3.1. Participant's Overview
    • 10.6.3.2. Financial Performance
    • 10.6.3.3. Product Benchmarking
    • 10.6.3.4. Recent Developments
  • 10.6.4. BIOMERIEUX
    • 10.6.4.1. Participant's Overview
    • 10.6.4.2. Financial Performance
    • 10.6.4.3. Product Benchmarking
    • 10.6.4.4. Recent Developments
  • 10.6.5. BD
    • 10.6.5.1. Participant's Overview
    • 10.6.5.2. Financial Performance
    • 10.6.5.3. Product Benchmarking
    • 10.6.5.4. Recent Developments
  • 10.6.6. QIAGEN
    • 10.6.6.1. Participant's Overview
    • 10.6.6.2. Financial Performance
    • 10.6.6.3. Product Benchmarking
    • 10.6.6.4. Recent Developments
  • 10.6.7. Quidel Corporation
    • 10.6.7.1. Participant's Overview
    • 10.6.7.2. Financial Performance
    • 10.6.7.3. Product Benchmarking
    • 10.6.7.4. Recent Developments
  • 10.6.8. F. Hoffmann-La Roche Ltd.
    • 10.6.8.1. Participant's Overview
    • 10.6.8.2. Financial Performance
    • 10.6.8.3. Product Benchmarking
    • 10.6.8.4. Recent Developments
  • 10.6.9. Danaher
    • 10.6.9.1. Participant's Overview
    • 10.6.9.2. Financial Performance
    • 10.6.9.3. Product Benchmarking
    • 10.6.9.4. Recent Developments
  • 10.6.10. Quest Diagnostics Incorporated
    • 10.6.10.1. Participant's Overview
    • 10.6.10.2. Financial Performance
    • 10.6.10.3. Product Benchmarking
    • 10.6.10.4. Recent Developments
  • 10.6.11. Agilent Technologies, Inc.
    • 10.6.11.1. Participant's Overview
    • 10.6.11.2. Financial Performance
    • 10.6.11.3. Product Benchmarking
    • 10.6.11.4. Recent Developments

관련자료